Pelvic inflammatory disease (PID) is a clinical syndrome characterized by upper genital tract inflammation and frequently associated with sexually transmitted or genital tract microorganisms. The Centers for Disease Control and Prevention (CDC) has developed STD treatment guidelines intended to assist health care providers in selecting antibiotic treatment strategies based on objective clinical evidence. 1 Several studies over the past 2 decades have demonstrated poor provider adherence to recommended treatment for PID. [2] [3] [4] [5] The authors of these reports called for aggressive quality improvement measures to improve adherence to PID treatment guidelines. With an ongoing focus on improving quality of care, one would expect to see improvement in provider adherence to PID antibiotic regimens over the past decade.
additional antibiotic regimens for PID that are not currently listed in the guidelines as primary recommendations, perhaps because of insufficient evidence (eg, 1 or 2 small trials). 1, 7 Conducting clinical trials for PID outcomes is challenging and expensive; therefore, observational data may be useful in determining whether treatments ultimately lead to improved long-term outcomes. Clinical trials are often done in carefully selected patients who meet specific diagnostic criteria and who are monitored closely. One advantage of observational epidemiologic studies (eg, the NHAMCS) over clinical trials is that the study sample is often more generalizable to real-world clinical settings. Currently, there is little information from observational studies regarding the long-term outcomes following PID treatments. One small observational study confirmed that women with PID who received an antibiotic regimen without ceftriaxone were more likely to have continued signs and symptoms after 2 weeks, compared to women who receive a ceftriaxone-containing regimen. 9 However, more data from observational studies are needed to identify the long-term impacts of various treatment regimens in more generalized patient populations.
What strategies should be used to improve quality of care for outpatient PID? One study demonstrated that an aggressive training regimen in 1 hospital, including disseminations of treatment algorithms and guidelines, educational sessions for residents, faculty and nursing staff, medication availability, and standardized discharge instructions significantly increased the proportion of patients with PID who were treated according to CDC guidelines. 10 Another study found that a 1-page summary of treatment guidelines attached to a questionnaire significantly improved adherence to treatment guidelines for a written patient scenario for PID. 11 Electronic medical records may also help enhance adherence treatment, as they can provide specific recommendations once a healthcare provider enters a specific diagnosis. Consultation with a specialist was associated with a significantly improved adherence to treatment guidelines in the Shih study, 6 although it is possible that the women who received specialty consultation had more severe symptoms and were treated more aggressively. Each of these strategies has potential merit, but more must be known about the reasons that providers are not adherent to the guidelines in order to devise the optimal strategy. After more than 2 decades with no improvement in PID-related antibiotic guideline adherence, the CDC and others should strongly consider a systematic effort to measure facilitators and barriers to antibiotic guideline uptake and to assess the impact of guidelines on long-term health outcomes in generalizable populations.
In summary, the evidence suggests that the quality of care for outpatient PID is poor, at least in terms of adherence to specific treatment recommendations. When considering the quality of care provided for PID, the correct antibiotic prescription is only a part of the standard of practice for PID. In addition to making the correct diagnosis, providers should recommend partner treatment and notification and should counsel patients about PID prevention. 1 Additional research is needed to better understand provider barriers to treatment adherence, to confirm whether women who receive "off-guideline" treatment indeed have worse outcomes outside of clinical trials, and to evaluate strategies to improve provider adherence to treatment guidelines.
